Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. 1997

J T Noga, and T M Hyde, and M M Herman, and C F Spurney, and L B Bigelow, and D R Weinberger, and J E Kleinman
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.

BACKGROUND Previous postmortem studies of glutamate receptors and uptake sites have shown decreased D-aspartate (D-Asp) (a marker for the high affinity glutamate uptake site) and elevated (+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine maleate (MK-801) binding in the putamen in schizophrenia and elevated alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor binding in the caudate nucleus of schizophrenics who committed suicide. The relative effects of schizophrenia, suicide, and neuroleptic treatment in these findings is unclear. This study further explores binding to glutamate receptors (NMDA, kainic acid, and AMPA) and uptake sites in postmortem striatal structures in schizophrenics relative to three control groups (normal controls, neuroleptic-treated controls, and nonpsychotic suicides). METHODS We compared the binding densities of tritium-labeled ligands 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), kainic acid (KA), MK-801, and D-Asp, which target the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), KA, and N-methyl-D-aspartic acid (NMDA) ionotropic receptor sites and the glutamate uptake site, respectively, in postmortem striatal/accumbens tissue from six DSM-III-R schizophrenics, eight normal controls, eight neuroleptic-treated controls, and eight suicide victims using standard receptor autoradiographic methods. RESULTS Binding of [3H] CNQX (AMPA receptors) was significantly different among the four groups across the subdivisions of the striatum: caudate, putamen, and nucleus accumbens (ANOVA P = .0007, .002, and .004, respectively). The schizophrenia group had higher mean CNQX binding in the caudate nucleus than normal (P = .005) and neuroleptic controls (P = .006) but not suicides (P = .6), who were also higher than normals and neuroleptic-treated controls (P = .05). The binding densities of tritiated MK-801, KA, and D-Asp were not significantly different among the four groups of subjects in any of the striatal regions examined. CONCLUSIONS The data suggest there may be an increased density of AMPA receptor sites in the caudate nucleus in schizophrenia that is not apparently due to neuroleptic treatment. A similar increase was also seen the suicide group. Although these data do not confirm previous reports of an increase in [3H]MK-801 or a decrease in [3H]D-Asp binding in the basal ganglia in schizophrenia, the increased caudate AMPA binding observed here could reflect decreased cortical glutamatergic innervation of the caudate. Its implication for suicide is unclear.

UI MeSH Term Description Entries
D007608 Kainic Acid (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose. Digenic Acid,Kainate,Acid, Digenic,Acid, Kainic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001923 Brain Chemistry Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states. Chemistry, Brain,Brain Chemistries,Chemistries, Brain
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001224 Aspartic Acid One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter. (+-)-Aspartic Acid,(R,S)-Aspartic Acid,Ammonium Aspartate,Aspartate,Aspartate Magnesium Hydrochloride,Aspartic Acid, Ammonium Salt,Aspartic Acid, Calcium Salt,Aspartic Acid, Dipotassium Salt,Aspartic Acid, Disodium Salt,Aspartic Acid, Hydrobromide,Aspartic Acid, Hydrochloride,Aspartic Acid, Magnesium (1:1) Salt, Hydrochloride, Trihydrate,Aspartic Acid, Magnesium (2:1) Salt,Aspartic Acid, Magnesium-Potassium (2:1:2) Salt,Aspartic Acid, Monopotassium Salt,Aspartic Acid, Monosodium Salt,Aspartic Acid, Potassium Salt,Aspartic Acid, Sodium Salt,Calcium Aspartate,Dipotassium Aspartate,Disodium Aspartate,L-Aspartate,L-Aspartic Acid,Magnesiocard,Magnesium Aspartate,Mg-5-Longoral,Monopotassium Aspartate,Monosodium Aspartate,Potassium Aspartate,Sodium Aspartate,Aspartate, Ammonium,Aspartate, Calcium,Aspartate, Dipotassium,Aspartate, Disodium,Aspartate, Magnesium,Aspartate, Monopotassium,Aspartate, Monosodium,Aspartate, Potassium,Aspartate, Sodium,L Aspartate,L Aspartic Acid
D001345 Autoradiography The making of a radiograph of an object or tissue by recording on a photographic plate the radiation emitted by radioactive material within the object. (Dorland, 27th ed) Radioautography
D001479 Basal Ganglia Large subcortical nuclear masses derived from the telencephalon and located in the basal regions of the cerebral hemispheres. Basal Nuclei,Ganglia, Basal,Basal Nuclear Complex,Ganglion, Basal,Basal Nuclear Complices,Nuclear Complex, Basal,Nuclei, Basal
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

J T Noga, and T M Hyde, and M M Herman, and C F Spurney, and L B Bigelow, and D R Weinberger, and J E Kleinman
January 1992, Psychopharmacology,
J T Noga, and T M Hyde, and M M Herman, and C F Spurney, and L B Bigelow, and D R Weinberger, and J E Kleinman
January 2020, Journal of psychiatric research,
J T Noga, and T M Hyde, and M M Herman, and C F Spurney, and L B Bigelow, and D R Weinberger, and J E Kleinman
March 2000, Schizophrenia research,
J T Noga, and T M Hyde, and M M Herman, and C F Spurney, and L B Bigelow, and D R Weinberger, and J E Kleinman
December 2002, The American journal of psychiatry,
J T Noga, and T M Hyde, and M M Herman, and C F Spurney, and L B Bigelow, and D R Weinberger, and J E Kleinman
March 2002, The American journal of psychiatry,
J T Noga, and T M Hyde, and M M Herman, and C F Spurney, and L B Bigelow, and D R Weinberger, and J E Kleinman
June 1981, Lancet (London, England),
J T Noga, and T M Hyde, and M M Herman, and C F Spurney, and L B Bigelow, and D R Weinberger, and J E Kleinman
May 1981, Lancet (London, England),
J T Noga, and T M Hyde, and M M Herman, and C F Spurney, and L B Bigelow, and D R Weinberger, and J E Kleinman
January 1999, Synapse (New York, N.Y.),
J T Noga, and T M Hyde, and M M Herman, and C F Spurney, and L B Bigelow, and D R Weinberger, and J E Kleinman
February 1998, Synapse (New York, N.Y.),
J T Noga, and T M Hyde, and M M Herman, and C F Spurney, and L B Bigelow, and D R Weinberger, and J E Kleinman
September 2007, Journal of psychiatry & neuroscience : JPN,
Copied contents to your clipboard!